Clinical trials

Condition   Drug Name  
Study (-)-Epigallocatechin gallate in seborrheic dermatitis
Design Randomized; Double-blind
Patients 100
Treatment Regimen (-)-Epigallocatechin gallate top. b.i.d. x 4 wks; Placebo
Conclusions (-)-Epigallocatechin gallate was well tolerated and significant reduced the mean inflammatory lesion count compared to placebo in patients with seborrheic dermatitis
Reference(s) Management of seborrheic dermatitis with 2% polyphenone (-)EGCg hydrophilic cream. A placebo-controlled, double-blind study
16th Congr Eur Acad Dermatol Venereol (EADV) (May 16 2007 , Vienna) 2007:Abst P264.
Author and Affiliation Syed, T., Wong, W.H.W., Benipoor, S., Ahmad, S.A., Govil, V., Aly, R.